New Tool for Prostate Cancer
As most people know, prostate cancer is one of the leading causes of death from cancer in men.
Treatment strategies range from surgery, to radiation to hormonal therapy, to seed implants and to castration.
Who benefits most from the different strategies is always hard to decide, but there is a new tool that has been developed to help physicians determine which high-risk prostate cancer patients will benefit from hormone therapy.
Researchers from the Fox Chase Cancer Center developed a prediction tool that “uses a patient’s clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.”
Hormonal therapy can have severe side effects that are often not worth the benefits that the therapy provides and therefore remains controversial and sometimes underutilized.
This new tool incorporates disease burden and individualizes treatment recommendations by entering each patient’s clinical information and thereby getting an estimate of the probability of the cancer coming back using different durations of hormone therapy.
This tool is different from what is currently available because it personalizes and estimates the benefits of different lengths of hormone therapy for the individual.
The tool bases conclusions on two main factors determined by a biopsy, “the percent of cancer-positive tissue identified and the percent of that positive tissue with a Gleason grade of four or five.”
Data supporting the tool was recently presented by Pahlajani at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology, held in Boston, MA.
The following link also has some more information.(Prostate cancer).
Treatment strategies range from surgery, to radiation to hormonal therapy, to seed implants and to castration.
Who benefits most from the different strategies is always hard to decide, but there is a new tool that has been developed to help physicians determine which high-risk prostate cancer patients will benefit from hormone therapy.
Researchers from the Fox Chase Cancer Center developed a prediction tool that “uses a patient’s clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.”
Hormonal therapy can have severe side effects that are often not worth the benefits that the therapy provides and therefore remains controversial and sometimes underutilized.
This new tool incorporates disease burden and individualizes treatment recommendations by entering each patient’s clinical information and thereby getting an estimate of the probability of the cancer coming back using different durations of hormone therapy.
This tool is different from what is currently available because it personalizes and estimates the benefits of different lengths of hormone therapy for the individual.
The tool bases conclusions on two main factors determined by a biopsy, “the percent of cancer-positive tissue identified and the percent of that positive tissue with a Gleason grade of four or five.”
Data supporting the tool was recently presented by Pahlajani at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology, held in Boston, MA.
The following link also has some more information.(Prostate cancer).
posted by Anonymous at 5:44 AM
1 Comments:
Have a Happy Thanksgiving, Doc.
Mark
Post a Comment
<< Home